Video

Dr. Gomella on Radium-223 in Advanced Prostate Cancer

Leonard G. Gomella, MD, form the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the novel therapeutic radium-223, which is awaiting a decision from the FDA as a treatment for men with advanced prostate cancer.

Leonard G. Gomella, MD, professor and chair of the Department of Urology at the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the novel therapeutic radium-223 (alpharadin), which is awaiting a decision from the FDA as a treatment for men with advanced prostate cancer.

The field of prostate cancer seems to attract novel therapeutic approaches, such as the personalized immunotherapy sipuleucel-T (Provenge), Gomella notes. Additionally, if approved in this space, radium-223 would become the first alpha particle emitting agent.

Until radium-223 is approved, it is unclear where the FDA label will place it in the sequence. However, Gomella notes, clinical trials examining the agent denote its efficacy in bone metastatic prostate cancer, making it a potential candidate anywhere in the spectrum of treatment for advanced disease. However, Gomella is intrigued to discover where the exact FDA label places this treatment in the sequence.

Related Videos
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Tycel Phillips, MD
Giuseppe Curigliano, MD, PhD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Andrew Davis, MD
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer